Stocktoria
Evolent Health, Inc. EVH
Evolent Health, Inc. (EVH) earns a Piotroski F-score of 4/9 (mixed financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $1.9B at a -28.5% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -4.55 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Services · percentile among 982 companies
Percentile vs other Services companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 4/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.064 |
| Retained earnings / assets | -0.693 |
| EBIT / assets | -0.216 |
| Equity / liabilities | 0.28 |
Sector peers · similar-size Services companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| EVH | Evolent Health, Inc. | 4/9 | -3 | — | -26.6% |
| FC | FRANKLIN COVEY CO | 5/9 | 1.5 | 91.3 | -7% |
| IT | GARTNER INC | 6/9 | 3.6 | 12.4 | +3.7% |
| GOOG | Alphabet Inc. | 5/9 | 6.79 | 31.1 | +15.1% |
| MSFT | MICROSOFT CORP | 6/9 | 4.49 | 20.7 | +17.8% |
| META | Meta Platforms, Inc. | 4/9 | 5.34 | 23.1 | +22.2% |
| BABA | Alibaba Group Holding Ltd | 3/9 | — | — | +8.1% |
About Evolent Health, Inc.
Evolent Health, Inc., through its subsidiary, provides specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company offers integrated value-based care platform for health plan administration and management. It also provides administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients. In addition, the company provides Machinify Auth Intelligence, an artificial intelligence tool to aid nurses and physicians in completing clinical review of prior authorization requests. Evolent Health, Inc. was founded in 2011 and is headquartered in Arlington, Virginia.
FAQ
Is EVH financially healthy?
Evolent Health, Inc.'s Piotroski F-score is 4/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does EVH pay a dividend?
No, Evolent Health, Inc. does not currently pay a dividend.
How profitable is EVH?
In FY2025, Evolent Health, Inc. had a net margin of -28.5% and a return on equity of -128.7%.
What is the analyst price target for EVH?
The average Wall-Street price target for Evolent Health, Inc. is $5.88, about 41.1% above the recent price, from 13 analysts.
Is EVH a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Evolent Health, Inc.: a Piotroski F-score of 4/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.